| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.2 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | 0.077 | 0.2 |